SEC Tracker
Get the app

Foghorn Therapeutics FHTX

Foghorn Therapeutics appoints Kristian F. Humer as Chief Financial Officer

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 99.1
Press release
  • Reports an executive or board change (5.02)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Foghorn Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Omeros OMER public float $172M, Jun 30, 2025
  2. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  3. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  4. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  5. 4D Molecular Therapeutics FDMT public float $166M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.